These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

945 related items for PubMed ID: 30249507

  • 1. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S.
    Lancet; 2018 Oct 13; 392(10155):1330-1339. PubMed ID: 30249507
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.
    Lancet; 2018 Aug 25; 392(10148):650-661. PubMed ID: 30097359
    [Abstract] [Full Text] [Related]

  • 3. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF, Anderson CW.
    ACR Open Rheumatol; 2022 Jun 25; 4(6):486-491. PubMed ID: 35157371
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC, CNTO1959PSA2001 Study Group.
    Lancet; 2018 Jun 02; 391(10136):2213-2224. PubMed ID: 29893222
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D, Bingham CO, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S.
    Lancet; 2017 Mar 25; 389(10075):1206-1217. PubMed ID: 28215362
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators.
    Lancet; 2008 May 17; 371(9625):1675-84. PubMed ID: 18486740
    [Abstract] [Full Text] [Related]

  • 7. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M.
    Lancet; 2021 Feb 06; 397(10273):487-498. PubMed ID: 33549193
    [Abstract] [Full Text] [Related]

  • 8. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
    van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Fei K, Gordon RM, Gregan I, Lo KH, Chevrier M, Rose S.
    Arthritis Rheumatol; 2020 May 06; 72(5):761-768. PubMed ID: 31769212
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group.
    Lancet; 2011 Feb 26; 377(9767):721-31. PubMed ID: 21296403
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
    van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Gordon RM, Fei K, Lo KH, Chevrier M, Rose S, Berry P, Yao Z, Karyekar CS, Zuraw Q.
    J Rheumatol; 2022 Apr 26; 49(4):380-387. PubMed ID: 34853089
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators.
    Lancet; 2008 May 17; 371(9625):1665-74. PubMed ID: 18486739
    [Abstract] [Full Text] [Related]

  • 12. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW.
    Lancet; 2018 Jul 21; 392(10143):222-231. PubMed ID: 30043749
    [Abstract] [Full Text] [Related]

  • 13. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, Ustekinumab MS Investigators.
    Lancet Neurol; 2008 Sep 21; 7(9):796-804. PubMed ID: 18703004
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
    McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK, PSUMMIT 1 Study Group.
    Lancet; 2013 Aug 31; 382(9894):780-9. PubMed ID: 23769296
    [Abstract] [Full Text] [Related]

  • 15. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA, Weinberg MA, Morris A, Reich K.
    Lancet; 2021 Apr 24; 397(10284):1564-1575. PubMed ID: 33894834
    [Abstract] [Full Text] [Related]

  • 16. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
    Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A.
    Lancet; 2009 Feb 21; 373(9664):633-40. PubMed ID: 19217154
    [Abstract] [Full Text] [Related]

  • 17. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May 07; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M.
    Lancet; 2016 Jan 02; 387(10013):40-52. PubMed ID: 26454361
    [Abstract] [Full Text] [Related]

  • 20. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L, STARDUST study group.
    Lancet Gastroenterol Hepatol; 2022 Apr 02; 7(4):294-306. PubMed ID: 35120656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.